Patients with advanced desmoplastic melanoma have high response to single-agent anti-programmed death protein 1 (PD-1) ...

Topline results were announced from a phase 3 trial evaluating Cylembio (imsapepimut and etimupepimut, adjuvanted) in combination with pembrolizumab as a first-line treatment for advanced melanoma.

Personalized vaccines are currently being investigated for the treatment of patients with kidney cancer; however, the ...

PD-1 Inhibitor Drug PD-1 Inhibitor Drugs Market poised for robust growth, driven by rising cancer therapies and expanding immuno-oncology a ...

Only patients who received rituximab, ipilimumab plus nivolumab, and trastuzumab plus pertuzumab had infusion-related reactions in the real-world cohort.

Cancer’s future may lie in combination therapy—pairing treatments to outsmart tumors, boost survival, and bring new hope ...

Breast cancer is the second most common cancer among women and the second leading cause of cancer-related deaths among women in the US. In light of Breast Cancer Research Awareness Day, The American ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech', HKEX: 6990) announced that clinical data from a Phase II study evaluating novel TROP2 antibody-drug conjugate (ADC) sacituzumab ...

HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing ...

A woman from Harrogate is embarking on an epic cycling journey from Land’s End to John o’Groats to honour her late husband.

AEMD READ THE FULL AEMD RESEARCH REPORT ENROLLMENT FOR ONCOLOGY TRIAL COHORT 2 HAS COMMENCED Data Safety Monitoring Board Recommended AEMD Progress Trial Without Modification Aethlon Medical ...